Should I Buy CMND? CMND 2026 Analysis

Should You Buy Clearmind Medicine Inc (CMND) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.350

1 Day change

-6.90%

52 Week Range

58.000

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: price is in a clear downtrend (SMA_200 > SMA_20 > SMA_5) with no proprietary buy signals.
No near-term catalysts (no recent news) and pattern-based outlook points to downside over the next month (-6.23% expected drift).
Financial picture remains weak (no revenue; losses and EPS deterioration YoY), which reduces confidence in a sustained bounce.
With an impatient entry profile (unwilling to wait for optimal setups), risk/reward is unfavorable at current levels—better to avoid or exit.

Technical Analysis

Trend: Bearish structure with moving averages stacked bearishly (SMA_200 > SMA_20 > SMA_5), indicating persistent downside momentum.
Momentum: MACD histogram is positive (0.217) but positively contracting—suggests any rebound momentum is fading rather than strengthening.
RSI: RSI_6 at 26.59 signals oversold conditions, which can spark short bounces, but oversold alone is not a durable buy signal in a broader downtrend.
Levels: Current price ~2.07 is below pivot (2.412) and near support zone (S1 2.114 already breached; next S2 1.93). Resistance levels to reclaim for trend improvement: pivot 2.412 then R1 2.71.
Intellectia Proprietary Trading Signals: No signal on given stock today. (AI Stock Picker: no signal; SwingMax: no signal recently.)

Positive Catalysts

- Oversold RSI may allow a short-lived technical bounce if price holds above ~1.93 (S2).
- Any future clinical/regulatory updates could act as catalysts, but none are present in the provided data.

Neutral/Negative Catalysts

- Strong bearish trend (MA stack) increases odds that rebounds fail and price revisits/ breaks lower supports.
- No news in the last week: lack of catalysts reduces probability of an immediate reversal.
- Similar-pattern projection implies negative 1-month bias (-6.23%).
- Ownership/trading signals: Hedge funds neutral; insiders neutral—no supportive accumulation signal.
- No recent congress trading data available; no influential buying/selling signal from that channel.

Financial Performance

Latest quarter: 2025/Q4.
Revenue: 0 (no YoY growth).
Net income: -687,842, down 22.26% YoY (loss widened).
EPS: -5.03, down 41.98% YoY (deteriorating per-share performance).
Overall: continuing losses with no revenue base—fundamentals do not support a confident “buy now” thesis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data provided, so Wall Street sentiment/trend cannot be assessed from the dataset.

Analyst Rating

Wall Street analysts forecast CMND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMND is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold